A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive Decline

NCT05199142 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Development plan changed

Conditions

Cognitive Decline

Interventions

DRUG: SDI-118
DRUG: Placebo

Sponsor

Syndesi Therapeutics